General Information of Drug (ID: DM735FA)

Drug Name
IMO-2125 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Hepatitis C virus infection 1E51.1 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM735FA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Toll-like receptor 9 (TLR9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cadi-05 DMPTCYB Prostate cancer 2C82.0 Phase 3 [3]
SD-101 DMAMTGI Hepatitis C virus infection 1E51.1 Phase 3 [4]
MGN-1703 DMCJRL1 Colorectal cancer 2B91.Z Phase 3 [5]
Tilsotolimod DMGYK2N Melanoma 2C30 Phase 3 [6]
MIS-416 DM7K4YR Autoimmune diabetes 5A10 Phase 2 [7]
IMO-3100 DMM549D Psoriasis vulgaris EA90 Phase 2 [8]
BL-7040 DMSBPJI Inflammatory bowel disease DD72 Phase 2 [9]
CYT003 DM4LJH8 Asthma CA23 Phase 2 [10]
CpG-10101 DM6MUCX Hepatitis C virus infection 1E51.1 Phase 2 [11]
JVRS-100 DMPMU38 leukaemia 2A60-2B33 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 9 (TLR9) TTSHG0T TLR9_HUMAN Agonist [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
3 Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
4 Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
5 Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
6 Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
7 DOI: 10.1371/journal.pone.0087712
8 Company report (Iderapharma)
9 Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
10 CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
11 Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.
12 Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820.